Tag: Reuters

Posted on

UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents – Reuters


Channel News Asia

UPDATE 2-FDA panel backs Glaxo asthma drug for adults, not adolescents
Reuters
The panel voted 16-4 that Breo Ellipta should be approved for once daily treatment of asthma in adults 18 years and older. It voted 19-1 that the data did not support approval for use in children aged 12 to 17. The FDA is not obliged to follow the …
U.S. Panel Backs Glaxo's Breo for Adults With Asthma, Not KidsBloomberg
GSK's Breo for asthma? FDA panel says yes–but only in adultsFiercePharma
FDA panel backs Glaxo asthma drug for adults, not adolescentsBusiness Insider
WallStreet.org –Fox Business
all 26 news articles »

View full post on asthma – Google News

Posted on

FDA panel backs Glaxo asthma drug for adults, not adolescents – Reuters


Channel News Asia

FDA panel backs Glaxo asthma drug for adults, not adolescents
Reuters
The panel voted 16 to 4 that the product, Breo Ellipta, should be approved for once daily treatment of asthma in adults 18 years and older. It voted 19 to 1 that the data did not support approval for use in children aged 12 to 17. The FDA is not …
Critical inspection of GlaxoSmithKline plc (ADR) (NYSE:GSK) by FDA …WallStreet.org
FDA panel backs Glaxo inhaler for adults, not adolescentsTown Hall
GSK and Theravance Announce Outcome of US FDA Advisory Committee on …MarketWatch
Healio
all 12 news articles »

View full post on asthma – Google News

Posted on

FDA staff finds no new safety problems with Glaxo’s asthma drug – Reuters


Reuters

FDA staff finds no new safety problems with Glaxo's asthma drug
Reuters
(Reuters) – GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found. The review comes two …
Ad Comm meeting approaches for expanded indication for Glaxo's COPD med …Seeking Alpha (registration)

all 5 news articles »

View full post on asthma – Google News

Posted on

AstraZeneca’s patent on asthma drug invalidated by US court – Reuters


Reuters

AstraZeneca's patent on asthma drug invalidated by US court
Reuters
NEW YORK (Reuters) – A U.S. federal judge ruled late on Friday that AstraZeneca PLC's patent on its Pulmicort Repsules treatment for asthma was invalid, opening up the market to a second, cheaper generic version. Actavis Plc said that the U.S. District …
Actavis launches Pulmicort Respules generic on AZ legal lossPharmaTimes

all 7 news articles »

View full post on asthma – Google News

Posted on

Big city life may not be a key asthma risk: US study – Reuters

Big city life may not be a key asthma risk: US study
Reuters
CHICAGO (Reuters) – The simple fact of growing up in a big city may not be a major factor in whether a child develops asthma, according to a new study that contradicts decades of public health assumptions about the so-called inner city asthma epidemic.
Asthma is not more prevalent in the inner city, researchers sayWashington Post
Public Release: 20-Jan-2015 Time to rethink the inner-city asthma epidemic?EurekAlert (press release)
Researchers Rethink Inner-City Asthma TheoryPhilly.com

all 14 news articles »

View full post on asthma – Google News

Posted on

Britain’s Vectura collaborates with Janssen in asthma, COPD – Reuters

Britain's Vectura collaborates with Janssen in asthma, COPD
Reuters
Janssen, a unit of Johnson & Johnson, will then use Vectura's dry powder inhaler technologies in the development of inhaled therapeutics for airways-related diseases such as asthma, a market worth in excess of $46 billion worldwide, Vectura said …
Vectura Signs Global Development And Licence Deal With Janssen In Asthma …RTT News
Vectura links with Janssen on asthma/COPD drug developmentThe Pharma Letter
Vectura In Deal With Johnson & Johnson's Janssen Biotech For AsthmaLondon South East
Business Weekly
all 6 news articles »

View full post on asthma – Google News

Posted on

Sanofi’s dual-action biotech asthma drug performs well in test – Reuters

Sanofi's dual-action biotech asthma drug performs well in test
Reuters
Nov 11 (Reuters) – An experimental biotech drug for severe asthma from France's Sanofi and its U.S. partner Regeneron has produced good results in clinical tests, suggesting its dual-action mechanism may be highly effective. Dupilumab is a latecomer …
Regeneron and Sanofi Announce Positive Results from Phase 2b Study of …SYS-CON Media (press release)
Regeneron, Sanofi Say Phase 2b trial of Dupilumab Meets Primary EndpointRTT News

all 5 news articles »

View full post on asthma – Google News

Posted on

Pay attention to pollution to combat asthma symptoms: case study – Reuters


TheHealthSite

Pay attention to pollution to combat asthma symptoms: case study
Reuters
NEW YORK (Reuters Health) – For a 38-year old professor who cycled to work every day, asthma symptoms tended to be worst in midmorning and early afternoon on weekdays, but improved noticeably on weekends. Her doctor suspected the air pollution on …
Manage asthma better by reducing exposure to pollutionTheHealthSite
Less Pollution Exposure Improves Asthma SymptomsHeadlines & Global News
Does your child with a food allergy or asthma have an action plan?Philly.com (blog)
News-Medical.net –Healio
all 16 news articles »

View full post on asthma – Google News